Open the mobile version, with barcode scanning
Class II Ongoing

Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591;…

Why: Lack of Assurance of Sterility

Company
Regeneron Pharmaceuticals Inc
Tarrytown, NY, United States
Reported
Aug 26, 2026
Recall started
Jul 28, 2026
Where sold
USA Nationwide
Amount
21,353 vials
Full product description
Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01
Lots / codes affected
Lot: 8494000002, Exp 7/31/28

Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.